Management Team

  • Our Company

Our Expert Management Team

The Executive Team at Immuron is made up of extraordinarily talented individuals who bring to the company years of experience in their respective fields and have proven expertise in building innovative pipelines.  Our team’s experience spans the full spectrum of discovery, clinical, regulatory and commercial with a strong track record in execution.  We are focused on capitalizing on the programs we prioritize and to bring life saving medicines to patients who suffer from the diseases we target.

 

 

 

Our Team

Thomas Liquard

Thomas Liquard

Cheif Executive Officer (CEO)

Mr. Liquard has held various commercialisation, product development and leadership roles with large pharma and biotech companies and holds an MBA from Columbia Business School and a Bachelor of Science degree from the University of Southern California.

From 2013 to 2014, Mr. Liquard was COO and later CEO of Australian Biotech Company Alchemia where he managed an annual operating budget of $22M, brought two major investors onto the register and led all major business development and corporate development activities for the Company.

Prior to joining Alchemia Mr. Liquard spent seven years with Pfizer in New York where he held various senior commercial positions in business and portfolio development, including the management of more than 70 projects at various stages of conclusion.

Mr Liquard also spent three years as a key member of Pfizer's Established Products US brands P&L Leadership Team where he engineered the groups $700M acquisition of Next Wave Pharmaceuticals, Inc (NextWave).  Mr. Liquard led the pre and post acquisition integration efforts of Next Wave into the existing Pfizer business.

Jerry Kanellos

Jerry Kanellos

Chief Operating and Scientific Officer

Dr Jerry Kanellos has over twenty years’ experience in the pharmaceutical and biotechnology industry, and has held leadership roles in business development, project management, intellectual property portfolio management research and development and senior management, and holds a PhD in medicine from the University of Melbourne.

Dr Kanellos spent five years with TransBio Limited where as Chief Operating Officer, he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along with development, management  and maintenance responsibility for the intellectual property portfolio, research and development and technology transfer.

Prior to this, Dr Kanellos worked for five years as a consultant to the biotech industry and has provided development and commercialisation strategies for various bodies including academic institutes, private and publicly listed companies and government departments. He has also been involved in the establishment and management of several startup biotechnology companies.

During his ten years tenure in research and development at CSL Limited, Dr Kanellos gained considerable experience in the drug development process, formulation development through to pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls (CMC) programs for the approval, manufacture and launch of several products.

Dan Peres

Dan Peres

Medical Director

Dr Peres has served in various clinical and medical managerial roles in pharmaceutical and medical device companies such as Exalenz Bioscience, CarboFix Orthopedics Ltd, NMB Medical Applications Ltd, ByPass Makafim Ltd, IOPtima Ltd and NovoNordisk Israel.  In addition, Dr Peres has been responsible for operational, marketing and business development activities throughout his career in the life sciences industry. Dr Peres began his career as a physician and medical director in various roles in the Israel army.

Dr Peres’ expertise lies with medical strategy, research and development, and the management of clinical studies and other laboratory processors. He has extensive knowledge of the leading International Centers for Liver Disease and established relationships with key Opinion leaders, including those currently participating in Immuron’s NASH and ASH trials. Dr Peres has been a certified physician since 2002 when he graduated from the Sackler School of Medicine at Tel-Aviv University.

Travis  Robins

Travis Robins

Director of US Sales

Travis is an accomplished, motivated leader with progressive years of proven success in dramatically increasing revenues and expanding market shares, while building key relationships. Building and leading top performing sales teams that embrace the highest standards of customer relationship management and retention. Excels at interacting with broad populations including senior management, staff, manufacturers, distributors, clinical professionals at physician practices, hospitals, government accounts, such as the VA, National and Regional accounts, clinics and universities. Effectively defines, develops and implements targeted action plans to maximize productivity, efficiency and profitability. Highly versatile; quickly masters new roles, responsibilities, technologies, and environments. Reputation for integrity, problem solving abilities, work ethic, and analytical skills.

Peter Vaughan

Peter Vaughan

Joint-Company Secretary & Chief Financial Officer (CFO)

Peter Vaughan is a Chartered Accountant who has worked in the listed company environment across a range of industries for more than 13 years. He has served on, and provided accounting, administration, compliance and general management services to, a number of private, not-for-profit and public company boards of directors and related committees. Peter is currently completing his Senior Executive MBA from Melbourne University.

Reza Moussakhani

Reza Moussakhani

Manufacturing Quality Director

Mr Moussakhani MEng. (CP), Grad. Cert. (Eng Mgt), BSc. (Chemistry), Dip. Bus. (FM), is a professional operations and production manager with over 25 years experience in the implementation of project, quality and process improvements in the manufacture of therapeutics. He has effectively managed all aspects of goods manufacturing practice production and worked with companies such as Hospira, Sigma Pharmaceuticals, Ensign Laboratories and Quantum.

Neta Tobis

Neta Tobis

Clinical Director

Ms. Tobis joined Immuron with 8 years of project management experience regarding multi-national clinical studies in diverse therapeutic areas including Gastroenterology, Diabetes Mellitus, Oncology, Haematology, Cardiology, Neurology and Dermatology. During that time period she managed projects for leading major pharmaceutical companies, including Pfizer, Novartis, Roche, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer and Ingelheim.

Ms. Tobis expertise lies with the clinical operational as well as regulatory aspects of the clinical trials, from mega clinical trials recruiting thousands of patients, to small niche projects including highly selective protocols of only a few dozen.
In her last position she spent 5 years in the global CRO Company - PPD ltd, as Lead CRA responsible for multi-national teams within multiple clinical studies.

Ms. Tobis holds Bio-Medical MBA from the Business school of the College of Management Academic Studies in Rishon LeZion and a Bachelor of Science degree in Biotechnology from the Tel Aviv University.

Phillip Hains

Phillip Hains

Joint-Company Secretary & Chief Financial Officer (CFO)

Phillip Hains is a Chartered Accountant and specialist in the public company environment who has served the needs of a number of public company boards of directors and related committees. He has over two decades of experience in providing accounting, administration, compliance and general management services. Holding a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants, Mr Hains is currently a Non-Executive Director of Savcor Limited (ASX:SAV) and of Non-For-Profit organisation Outward Bound Australia.